ClinicalTrials.gg
CompletedNCT01042730Updated May 17, 2021

Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REAL-CAD)

An interventional study of Pitavastatin 1 mg daily or 4 mg daily in Coronary Artery Disease, sponsored by Juntendo University. Completed at 2 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-05-17.

Sponsored by Juntendo University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
13,054
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Coronary Artery Disease with a site in Japan — 12 open to participants now, 21 under way, 2 of them phase 3. Coronary Artery Disease · Japan.

Enrollment
5th of 100
13,054 · median 445
Started
2010
with 18 others
No phase
39 of 134
5 open now
Registered
21st of 134
by date

Among the 134 studies in Coronary Artery Disease with a site in Japan, this one is the 5th largest by enrollment of the 100 interventional ones that give a count, is one of 19 that started in 2010, is one of 39 with no phase, and was the 21st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

12 of the 134 studies in Coronary Artery Disease with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Coronary Artery Disease with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the prevention of cardiovascular disease by moderate cholesterol lowering therapy, pitavastatin 1mg/day or aggressive cholesterol lowering therapy, pitavastatin 4mg/day in patients with stable coronary artery disease.

Read the detailed description

It was already demonstrated by previous clinical trials that statins lower the incidence of death and cardiovascular events in patients with coronary artery disease. However, whether aggressive cholesterol lowering therapy, using high dosage of statins, is more effective than moderate cholesterol lowering therapy for the prevention of cardiovascular events in patients with coronary artery disease has not been studied in Japan.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Pitavastatin
  • Coronary Artery Disease
  • Cardiovascular Disease
04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients who met following all criteria are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when was given. (Primary registration)
  • Coronary artery disease patients meeting one of the following events

    • History of Acute Coronary Syndrome (AMI or Unstable angina)
    • History of revascularization (PCI or CABG)
    • Diagnosis of ischemic heart disease and coronary artery stenosis as having 75% or higher stenosis according to the AHA classification
  • Hypercholesterolemia patients meeting one of following criteria

    • LDL-C is 140 mg/dL or over
    • LDL-C is 100 mg/dL or over and requiring cholesterol lowering drugs judged by attending physicians
    • Patents receiving cholesterol lowering drugs
  • Age (≧20 \<80 year-old)
  • Patients given written informed consent.

Exclusion Criteria:

Exclusion Criteria(Pre-Run-in period)

  • Patients planning revascularization
  • Malignant tumor in active phase
  • Patients who meet of LIVALO tablet below

    • Patients who have to LIVALO tablet
    • Patients who have severe liver dysfunction or biliary atresia
    • Patients who are being treated with cyclosporine
    • Pregnant women, women suspected of being pregnant, or lactating women
  • Patients who have heart failure III or greater
  • Patients undergoing dialysis
  • Patients with familial hypercholesterolemia
  • Patients registered in the other clinical trials
  • Patients taking prohibited drugs
  • Patients who are ineligible in the opinion of the investigator

Exclusion Criteria(Post-Run-in period)

  • LDL-C is 120mg/dL or over after Run-in period
  • Patients with occurrence of acute coronary syndrome (AMI or Unstable angina) within 3 months
  • Patients who have been undergone PCI or CABG within 3 months
  • Compliance is less than 50% in Run-in period
  • Patients who met primary endpoint in Run-in period.
  • Patients who met adverse events in Run-in period and judged as ineligible in the opinion of the investigator
  • Patients who are ineligible in the opinion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13,054 participants (actual)

Study arms

  • Active comparator
    Pitavastatin 1 mg daily

    Drug: Pitavastatin 1 mg daily or 4 mg daily

  • Active comparator
    Pitavastatin 4 mg daily

    Drug: Pitavastatin 1 mg daily or 4 mg daily

Interventions

  • DrugPitavastatinStudies of PitavastatinPitavastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.

    Also known as: LIVALO Tablet

06

What researchers measure

Primary outcomes

  1. Occurrence of one of following events(Cardiovascular death, Non-fatal Myocardial Infarction (MI), Non-fatal Cerebral Infarction (CI), Unstable angina requiring urgent hospitalization)

    Time frame: 3-6 years

Secondary outcomes

  1. Composite cardiovascular events

    Time frame: 3-6 years

  2. Composite coronary heart disease events

    Time frame: 3-6 years

  3. Composite cerebrovascular events

    Time frame: 3-6 years

  4. Death events

    Time frame: 3-6 years

  5. Heart disease events

    Time frame: 3-6 years

  6. Cerebrovascular events

    Time frame: 3-6 years

  7. The other events

    Time frame: 3-6 years

07

Study locations

2 sites
  • Kyoto University Hospital
    Kyoto, 606-8507, Japan
  • Juntendo University School of Medicine
    Tokyo, Japan
08

References and documents

Publications

  • Sakuma M, Iimuro S, Shinozaki T, Kimura T, Nakagawa Y, Ozaki Y, Iwata H, Miyauchi K, Daida H, Suwa S, Sakuma I, Nishihata Y, Saito Y, Ogawa H, Matsuzaki M, Ohashi Y, Taguchi I, Toyoda S, Inoue T, Nagai R. Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. BMC Med. 2022 Nov 14;20(1):441. doi: 10.1186/s12916-022-02633-5. PubMed 36372869 ↗
  • Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsuji Y, Kimura K, Takahashi J, Hirayama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation. 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615. Erratum In: Circulation. 2019 Apr 2;139(14):e836. doi: 10.1161/CIR.0000000000000676. PubMed 29735587 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Jun 2016, 76 months.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's 76 months is above that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2010
First posted
Jan 6, 2010
StartActual
Feb 2010
Primary completionActual
Jun 2016
CompletionActual
Nov 2017
Last update
May 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01042730
Lead sponsor
Juntendo University
Collaborators
Tokyo University, Yamaguchi University Hospital, Tohoku University, Kyoto University, Kumamoto University
Responsible party
Sponsor
First posted
Jan 6, 2010
Start date
Feb 2010
Primary completion
Jun 2016
Completion
Nov 2017
Last update
May 17, 2021

Study contacts

Ryozo Nagai, MD, PhD
principal investigator · Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine
Masunori Matsuzaki, MD, PhD
principal investigator · Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion